WEQUAL
15.12.2020 16:19:11 CET | Business Wire | Press release
Eight businesswomen holding prominent executive roles in leading companies in Europe, the Middle East and Africa have been named as winners in the annual WeQual Awards (www.wequal.com/awards ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005796/en/
WeQual identifies and recognises world-class women executives, one level below the group C-suite, and is designed to promote diversity and gender equality within the group executive committees of EMEA’s largest companies.
The eight winners were selected from a shortlist of 24 finalists. The successful award holders are employed in Aryzta, Bayer’s Consumer Health Division, Bureau Veritas, Fresenius Medical Care, Ooredoo Qatar, Sodexo, Standard Chartered Bank and Unilever.
Katie Litchfield, Founder and CEO of WeQual , says: “WeQual identifies already successful senior women who are qualified to be appointed to the group C-suite. Our mission is to tackle the slow progress in appointing diverse women to executive roles and highlight successes where they occur.
“The glass-ceiling concept has been an issue for decades, and the drop-off is steepest just below the group C-suite, so it is important to champion gender equality at the top.”
The awards come at an important time for women in business. The global Covid-19 pandemic is in danger of pushing back opportunities for women to be appointed to the most senior positions. “The fact that we are able to celebrate the achievements of these women in major companies at this time sets a shining example to others,” says Katie Litchfield.
The winners are:
− Bola Adesola : Senior Vice-Chairman, Africa, Standard Chartered Bank, Nigeria. Head of Region Category.
− Dr Cora Koppe-Stahrenberg : Executive Vice President, Global Head of Human Resources, Fresenius Medical Care, Germany. People Excellence Category .
− Munera AL-Dosari : Chief Strategy Officer, Ooredoo Qatar. Strategy Development Category .
− Patricia Amaro : Digital Hub and E-commerce Director, Unilever, Spain. Digital Impact Category .
− Patricia Corsi : Global Chief Marketing and Digital Officer, Bayer’s Consumer Health Division, Switzerland. Brand Innovation Category.
− Nathalie Pousin : Chief Financial Officer, France, Africa, GSIT, Bureau Veritas, France. Finance Category.
− Petra Melander : EMEA Account Director, Sodexo, Finland. Commercial Performance Category.
− Rebeca Navarro : Chief Transformation Officer for Europe and Head of Procurement, Aryzta, Switzerland. Transformational Leadership Category.
The 24 finalists were assessed against seven criteria: Leadership, Cognitive Ability, Integrity, Drive and Resilience, Equality, Knowledge of the Business, and Personal Development. All candidates were assessed blind with no name or company revealed in their application.
To choose the winners, eight executive interviewers held 30-minute interviews with the three finalists in each category before each choosing a category winner. The judges were:
− Sir Ian Cheshire, Chairman, Barclays UK
− Viswas Raghavan, CEO EMEA, J.P. Morgan
− Warren East, CEO, Rolls-Royce
− Dame Inga Beale, Chairperson, Mediclinic
− Chris O'Shea, CEO, Centrica
− Ron Kalifa OBE, Chairman, Network International
− Tamara Box, Managing Partner EME, Reed Smith LLP
− Tulsi Naidu, CEO, Zurich Insurance Company UK
All the 24 award finalists have been given access to a range of WeQual support services and networks designed to help them make the step up to the group executive level. A quarter of WeQual award winners in the UK and USA have since been promoted to the global executive committees of FTSE and Fortune 500 companies. There are now 96 senior women involved with WeQual globally.
(Ends)
Notes to editors
About WeQual
WeQual's mission is to make businesses more inclusive by identifying exceptional women executives and address the gender imbalance across the world's Group Executive Committees. Katie Litchfield, founder and CEO of WeQual Awards, devised the new platform which calls for women senior executives to build their case as to why they deserve to be appointed to the Group Executive Committee.
- LinkedIn: https://www.linkedin.com/company/wequal-awards
- Twitter: https://twitter.com/WeQualGlobal
- YouTube: https://www.youtube.com/channel/UCBpixTLeUsQVjwrivAP9-KA
- Facebook: https://www.facebook.com/WeQualAwards
- Instagram: https://www.instagram.com/wequalglobal
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005796/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom